Cencora (COR) Stock Price, News & Analysis

Company Overview

Cencora (NYSE: COR) is a leading global pharmaceutical distribution and services company, offering a comprehensive range of supply chain solutions to healthcare providers, biotechnology firms, and pharmaceutical manufacturers. The company specializes in the procurement, storage, and delivery of branded and generic pharmaceuticals, over-the-counter healthcare products, and specialty medications. Through a network of distribution centers and technology-driven logistics systems, Cencora ensures continuity of supply for a broad spectrum of therapeutic categories, supporting hospitals, pharmacies, and long-term care facilities worldwide.

In addition to its core distribution business, Cencora provides a suite of value-added services designed to enhance patient access and optimize medication management. These services include specialty pharmacy operations, medication adherence programs, patient support services, and regulatory compliance consulting. Cencora’s strategic partnerships with drug developers and biotech companies facilitate the launch of novel therapies, while its data analytics capabilities enable real-time visibility across the supply chain, helping clients navigate complex market dynamics and regulatory environments.

Originally formed in 2001 through the merger of AmeriSource Health Corporation and Bergen Brunswig Corporation, the company operated for many years under the AmerisourceBergen name. In October 2023, it rebranded as Cencora to reflect its broadened mission of connecting healthcare to people around the globe. Headquartered in Warrendale, Pennsylvania, Cencora maintains operations across North America, Europe, Asia Pacific, and select emerging markets, operating hundreds of distribution centers that adhere to stringent quality and safety standards.

Under the leadership of Chairman and Chief Executive Officer Steven H. Collis, Cencora continues to pursue strategic growth through acquisitions, technological innovation, and expanded service offerings. The company’s executive team emphasizes sustainability initiatives, digital transformation, and workforce development as key pillars for future growth. With a focus on strengthening global healthcare infrastructure and improving patient outcomes, Cencora remains a pivotal partner for stakeholders throughout the pharmaceutical value chain.

Key Stats

• Today's Range: $289.03 to $297.63
• 50-Day Range: $278.35 to $304.04
• 52-Week Range: $218.65 to $309.35
• Volume: 1.21 million shs
• Average Volume: 1.50 million shs
• Market Capitalization: $56.41 billion
• P/E Ratio: 33.77
• Dividend Yield: 0.76%
• Price Target: $306.33
• Consensus Rating: Moderate Buy

Cencora Stock Analysis - MarketRank™

Cencora scored higher than 93% of companies evaluated by MarketBeat, and ranked 79th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cencora has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 9 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Cencora has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 9.82%

Earnings Growth

Earnings for Cencora are expected to grow by 9.82% in the coming year, from $15.37 to $16.88 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cencora is 33.77, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.22.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cencora is 33.77, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.19.

Price to Earnings Growth Ratio

Cencora has a PEG Ratio of 1.46. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Cencora has a P/B Ratio of 72.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.61% of the float of Cencora has been sold short.

Short Interest Ratio / Days to Cover

Cencora has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cencora has recently increased by 0.76%, indicating that investor sentiment is decreasing.

Dividend

• Score: 3.3 / 5
• Dividend Strength: Strong

Dividend Yield

Cencora has a dividend yield of 0.74%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Cencora has been increasing its dividend for 15 years.

Dividend Coverage

The dividend payout ratio of Cencora is 25.52%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Cencora will have a dividend payout ratio of 13.03% next year. This indicates that Cencora will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 3.1 / 5
• Environmental Score: -0.77

Percentage of Shares Shorted

3.61% of the float of Cencora has been sold short.

Short Interest Ratio / Days to Cover

Cencora has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cencora has recently increased by 0.76%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 1.40

News Sentiment

Cencora has a news sentiment score of 1.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 30 news articles for Cencora this week, compared to 21 articles on an average week.

Search Interest

Only 5 people have searched for COR on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.

MarketBeat Follows

7 people have added Cencora to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Cencora insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,812,296.00 in company stock.

Percentage Held by Insiders

10.80% of the stock of Cencora is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

97.52% of the stock of Cencora is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

COR Stock Analysis - Frequently Asked Questions

How have COR shares performed this year?

Cencora's stock was trading at $224.68 at the beginning of 2025. Since then, COR stock has increased by 29.5% and is now trading at $291.0680.
View the best growth stocks for 2025 here.

How were Cencora's earnings last quarter?

Cencora, Inc. (NYSE:COR) announced its quarterly earnings data on Wednesday, May, 7th. The company reported $4.42 earnings per share for the quarter, beating the consensus estimate of $4.07 by $0.35. The company's quarterly revenue was up 10.3% compared to the same quarter last year.
Read the conference call transcript.

Does Cencora have any subsidiaries?

Cencora subsidiaries include Alliance Healthcare, H. D. Smith, St. Francis Group, PharMEDium Healthcare, MWI Veterinary Supply, World Courier, IntrinsiQ, and others.

Who are Cencora's major shareholders?

Top institutional shareholders of Cencora include Park National Corp OH (0.02%), Cullen Investment Group LTD. and Kera Capital Partners Inc.. Insiders that own company stock include Walgreens Boots Alliance, Inc, Steven H Collis, Robert P Mauch, Robert P Mauch, Dermot Mark Durcan, Lazarus Krikorian, Silvana Battaglia, Elizabeth S Campbell, Gina Clark, Gina Clark, Leslie E Donato and Leslie E Donato.
View institutional ownership trends.

How do I buy shares of Cencora?

Shares of COR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cencora own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cencora investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Broadcom (AVGO), Netflix (NFLX) and Tesla (TSLA).

Company Calendar

• Last Earnings: 5/07/2025
• Record date for 6/2 Dividend: 5/16/2025
• Ex-Dividend for 6/2 Dividend: 5/16/2025
• Dividend Payable: 6/02/2025
• Today: 7/03/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Health Care Distributors
• Current Symbol: NYSE:COR
• CIK: 1140859
• Web: www.amerisourcebergen.com
• Phone: (610) 727-7000
• Fax: 800-640-5221
• Employees: 46,000
• Year Founded: 2001

Price Target and Rating

• Average Stock Price Target: $306.33
• High Stock Price Target: $355.00
• Low Stock Price Target: $275.00
• Potential Upside/Downside: +5.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.82
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): $8.62
• Trailing P/E Ratio: 33.77
• Forward P/E Ratio: 18.94
• P/E Growth: 1.46
• Net Income: $1.51 billion
• Net Margins: 0.55%
• Pretax Margin: 0.74%
• Return on Equity: 344.71%
• Return on Assets: 4.26%

Debt

• Debt-to-Equity Ratio: 6.01
• Current Ratio: 0.87
• Quick Ratio: 0.52

Sales & Book Value

• Annual Sales: $293.96 billion
• Price / Sales: 0.19
• Cash Flow: $19.59 per share
• Price / Cash Flow: 14.86
• Book Value: $4.04 per share
• Price / Book: 72.05

Miscellaneous

• Outstanding Shares: 193,820,000
• Free Float: 172,890,000
• Market Cap: $56.41 billion
• Optionable: Optionable
• Beta: 0.57